J9250 – Methotrexate sodium, 5 mg
HCPCS Level II code · J codes: Drugs Administered Other Than Oral Method
HCPCS codeJ9250
- Long description
- Methotrexate sodium, 5 mg
- Short description
- Methotrexate sodium inj
- Pricing indicator
51Drugs- Medicare coverage
DSpecial coverage instructions apply- BETOS category
O1DChemotherapy- Added
- January 1, 1994
- Last change
- April 1, 2024 – No change
- Termination date
- March 31, 2024
Frequently asked questions
What is HCPCS code J9250?
J9250 is a HCPCS Level II code for methotrexate sodium, 5 mg. It was discontinued on March 31, 2024.
Does Medicare cover J9250?
The HCPCS file lists coverage code D: Special coverage instructions apply. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby J codes
- J9229 – Injection, inotuzumab ozogamicin, 0.1 mg
- J9230 – Injection, mechlorethamine hydrochloride, (nitrogen mustard), 10 mg
- J9232 – Injection, docetaxel (hospira), not therapeutically equivalent to j9171, 1 mg
- J9245 – Injection, melphalan hydrochloride, not otherwise specified, 50 mg
- J9246 – Injection, melphalan (evomela), 1 mg
- J9247 – Injection, melphalan flufenamide, 1mg
- J9248 – Injection, melphalan (hepzato), 1 mg
- J9249 – Injection, melphalan (apotex), 1 mg
- J9255 – Injection, methotrexate (accord), not therapeutically equivalent to j9260, 50 mg
- J9256 – Injection, nipocalimab-aahu, 3 mg
- J9258 – Injection, paclitaxel protein-bound particles (teva), not therapeutically equivalent to j9264, 1 mg
- J9259 – Injection, paclitaxel protein-bound particles (american regent), not therapeutically equivalent to j9264, 1 mg
- J9260 – Injection, methotrexate sodium, 50 mg
- J9261 – Injection, nelarabine, 50 mg
- J9262 – Injection, omacetaxine mepesuccinate, 0.01 mg
- J9263 – Injection, oxaliplatin, 0.5 mg
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.